Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer

Phase 1

Terminated

Conditions: Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma

Interventions: Drug: bevacizumab
Drug: 5-Fluorouracil
Drug: Oxaliplatin
Drug: gemcitabine
Procedure: External Beam Radiation Therapy

First Posted Date: 2006-03-28

Last Posted Date: 2009-08-10

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 52

Registration Number: NCT00307723

Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer

Phase 1

Completed

Conditions: Rectal Cancer
Adenocarcinoma of the Rectum

Interventions: Drug: 5-fluorouracil
Drug: bevacizumab
Drug: erlotinib
Procedure: External beam radiation therapy (EBRT)

First Posted Date: 2006-03-28

Last Posted Date: 2017-05-10

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 32

Registration Number: NCT00307736

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Phase 3

Completed

Conditions: Metastases
Colorectal Neoplasms
Colorectal Carcinoma

Interventions: Drug: Placebo
Drug: Xaliproden (SR57746A)
Drug: Oxaliplatin
Drug: 5-Fluorouracil
Drug: Leucovorin

First Posted Date: 2006-03-21

Last Posted Date: 2016-05-04

Lead Sponsor: Sanofi

Target Recruit Count: 879

Registration Number: NCT00305188

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom

Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Phase 3

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: cisplatin
Drug: fluorouracil
Drug: gemcitabine hydrochloride
Drug: leucovorin calcium

First Posted Date: 2006-03-17

Last Posted Date: 2014-03-04

Lead Sponsor: Federation Francophone de Cancerologie Digestive

Target Recruit Count: 202

Registration Number: NCT00303758

Locations: 🇫🇷
Centre Hospital Universitaire Hop Huriez, Lille, France
🇫🇷
Centre Hospitalier de Chalons-en-Champagne, Chalons-en-Champagne, France
🇫🇷
Hopital Saint Joseph, Marseille, France

and more 43 locations

Combination Chemotherapy as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Drug: fluorouracil
Drug: leucovorin calcium
Drug: irinotecan hydrochloride

First Posted Date: 2006-03-17

Last Posted Date: 2016-05-30

Lead Sponsor: Federation Francophone de Cancerologie Digestive

Target Recruit Count: 282

Registration Number: NCT00303771

Locations: 🇫🇷
Clinique De Rochebelle, Ales, France
🇫🇷
Centre hospitalier d'Alencon, Alencon, France
🇫🇷
Centre Hospitalier d'Abbeville, Abbeville, France

and more 74 locations

Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer

Phase 3

Terminated

Conditions: Stage III Rectal Cancer
Adenocarcinoma of the Rectum
Stage II Rectal Cancer

Interventions: Drug: oxaliplatin
Drug: fluorouracil
Drug: leucovorin calcium
Drug: bevacizumab

First Posted Date: 2006-03-17

Last Posted Date: 2023-07-06

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 355

Registration Number: NCT00303628

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 609 locations

Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery

Phase 3

Active, not recruiting

Conditions: Breast Cancer

Interventions: Biological: pegfilgrastim
Drug: capecitabine
Drug: cyclophosphamide
Drug: epirubicin hydrochloride
Procedure: adjuvant therapy
Drug: fluorouracil
Drug: methotrexate

First Posted Date: 2006-03-13

Last Posted Date: 2018-08-08

Lead Sponsor: Institute of Cancer Research, United Kingdom

Target Recruit Count: 4400

Registration Number: NCT00301925

Locations: 🇬🇧
Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom
🇬🇧
Sussex Cancer Centre at Royal Sussex County Hospital, Brighton, England, United Kingdom
🇬🇧
Burnley General Hospital, Burnley, England, United Kingdom

and more 147 locations

Radiation Therapy With or Without Chemotherapy Before Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Procedure: conventional surgery
Drug: fluorouracil
Drug: leucovorin calcium
Radiation: radiation therapy

First Posted Date: 2006-02-27

Last Posted Date: 2016-05-30

Lead Sponsor: Federation Francophone de Cancerologie Digestive

Target Recruit Count: 762

Registration Number: NCT00296608

Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)

Phase 1

Completed

Conditions: Gastrointestinal Neoplasms
Neoplasm Metastasis

First Posted Date: 2006-02-09

Last Posted Date: 2013-01-28

Lead Sponsor: University Hospital Tuebingen

Registration Number: NCT00289445

Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Childhood Central Nervous System Choriocarcinoma
Childhood Central Nervous System Embryonal Tumor
Childhood Central Nervous System Germ Cell Tumor
Childhood Central Nervous System Germinoma
Childhood Central Nervous System Mixed Germ Cell Tumor
Childhood Central Nervous System Teratoma
Childhood Central Nervous System Yolk Sac Tumor
Recurrent Childhood Brain Stem Glioma
Recurrent Childhood Central Nervous System Embryonal Tumor
Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Drug: oxaliplatin
Drug: fluorouracil
Drug: leucovorin calcium
Other: pharmacological study
Procedure: positron emission tomography
Procedure: computed tomography

First Posted Date: 2006-01-25

Last Posted Date: 2013-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT00281944

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy